跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
anti-BCMA CAR-T cell therapy (multiple myeloma)
首页
药物
anti-BCMA CAR-T cell therapy (multiple myeloma)
anti-BCMA CAR-T cell therapy (multiple myeloma)
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
ANTI-BCMA CAR T CELL COMPOSITIONS
EP 3534968 A4
申请人: BLUEBIRD BIO INC
优先权: 2016
CN
EP
US
WO
7 件公开
NOVEL DUAL SPLIT CAR-T CELLS FOR THE TREATMENT OF CD38-POSITIVE HEMATOLOGICAL MALIGNANCIES
EP 4583905 A1
申请人: INST NAT SANTE RECH MED
优先权: 2022
EP
WO
2 件公开
METHODS FOR TREATING MULTIPLE MYELOMA WITH CAR-T CELLS AND BISPECIFIC ANTIBODIES
US 20260041768 A1
申请人: JANSSEN BIOTECH INC
优先权: 2024
US
WO
2 件公开
Combination therapy of ATRA or other retinoic acid with immunotherapeutic agents that bind to BCMA
CN 115667303 A
申请人: UNIV WUERZBURG J MAXIMILIANS
优先权: 2020
CN
Combination of T cell therapy against BCMA with immunomodulatory compounds
CN 116157125 A
申请人: JUNO THERAPEUTICS INC
优先权: 2020
CN
Preparation method and application of BCMA-targeting tumor antigen receptor modified T cell
CN 112062864 A
申请人: FAN KEXING
优先权: 2020
CN
ANTI-BCMA SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC CONSTRUCTS
US 20250000976 A1
申请人: NAT RES COUNCIL CANADA
优先权: 2022
US
Chimeric antigen receptor simultaneously targeting GPRC5D and CS1 and application thereof
CN 119548624 A
申请人: JIANGSU TUOHONG KANGHENG PHARMACEUTICAL CO LTD
优先权: 2024
CN
药物
反馈
